Key facts
- It has raised $6.3M; the latest was Later Stage VC ($2.0M) in Jun 2025.
- Notable investors include Australian Government's Department of Health, BioCurate, GrantConnect, IP Group Australia, Jumar Bioincubator — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Inosi Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Inosi Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inosi Therapeutics
Developer of pharmaceutical therapy devices designed to treat fibrosis. The company provides a therapeutic approach with a mechanism of action that differentiates from current treatments ensuring that IRAP inhibitors can be trialed alone or safely combined with the existing standard of care to further improve the treatment of target organ damage associated with diabetes-induced kidney disease and cardiovascular disease, enabling healthcare providers to treat against a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2018
- Employees
- 6
- Website
- inositherapeutics.com/
- Ownership
- Privately Held (backing)
Inosi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inosi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inosi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.